https://charts.traderzeitung.de/phases/US8051111016
string(1443) "{"isin":"US8051111016","name":"Savara Inc","stock_id_xnas":7874906,"stock_id_xnys":null,"generated_at":"2026-08-21 11:51:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.37,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.6,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":4.2831},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":5.595,"close_at":"2026-08-19 22:00:00","complete":true,"perf_pct":-0.0893}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":5.55,"close_at":"2026-08-20 10:12:00","complete":true,"perf_pct":-0.8043},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.5,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-0.9009},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":5.48,"close_at":"2026-08-20 22:32:00","complete":true,"perf_pct":-0.3636}]}]}"
Savara Aktie News & Nachrichten
Trading-Room

Savara Aktie News & Nachrichten

[WKN: A2DQ2B | Symbol: SVRA]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Savara

Savara Inc.: Citizens JMP sieht 164 % Kurspotenzial bei dem auf seltene Atemwegserkrankungen spezialisierten Biotech

Fokus auf seltene Atemwegserkrankungen Savara Inc. (SVRA) ist ein Biotech, welcher sich auf die Entwicklung...

TOP-5-Kursziele der Analysten am 23.10.25

Savara Inc. [US8051111016] Citizens JMP bestätigt Buy-Rating und erhöht das Kursziel von 8 auf...

  • ‹
  • 1
  • ›
Savara Nachrichtenticker öffnen
MT Newswires 23.06.2026 10:05 Uhr

Savara Insider hat Aktien im Wert von $2.241.432 verkauft, laut einer aktuellen SEC-Einreichung

04:04 AM EDT, 06/23/2026 (MT Newswires) -- David L Lowrance, Chief Financial Officer, hat am 22. Juni 2026 394.528 Aktien von Savara (SVRA) für $2.241